Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA

Abstract Background (1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort. Results Forty-five thousand three hundred sixty pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vaibhav Rastogi, Ranjit Banwait, Devina Singh, Hale Toklu, Lexie Finer, Dipendra Parajuli, Latha Ganti
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Liver Pancreas Mortality SARS-CoV2 Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
Acceso en línea:	https://doaj.org/article/84440671453442d6a475304089dd969f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:84440671453442d6a475304089dd969f
record_format	dspace
spelling	oai:doaj.org-article:84440671453442d6a475304089dd969f2021-11-08T10:44:33ZPrevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA10.1186/s12245-021-00393-21865-13721865-1380https://doaj.org/article/84440671453442d6a475304089dd969f2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12245-021-00393-2https://doaj.org/toc/1865-1372https://doaj.org/toc/1865-1380Abstract Background (1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort. Results Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15–3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5–2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3–1.5 severe vs mild/moderate) and longer hospital length of stay (2 days). Conclusion COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury. Graphical AbstractVaibhav RastogiRanjit BanwaitDevina SinghHale TokluLexie FinerDipendra ParajuliLatha GantiBMCarticleLiverPancreasMortalitySARS-CoV2Medical emergencies. Critical care. Intensive care. First aidRC86-88.9ENInternational Journal of Emergency Medicine, Vol 14, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Liver Pancreas Mortality SARS-CoV2 Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
spellingShingle	Liver Pancreas Mortality SARS-CoV2 Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 Vaibhav Rastogi Ranjit Banwait Devina Singh Hale Toklu Lexie Finer Dipendra Parajuli Latha Ganti Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
description	Abstract Background (1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort. Results Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15–3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5–2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3–1.5 severe vs mild/moderate) and longer hospital length of stay (2 days). Conclusion COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury. Graphical Abstract
format	article
author	Vaibhav Rastogi Ranjit Banwait Devina Singh Hale Toklu Lexie Finer Dipendra Parajuli Latha Ganti
author_facet	Vaibhav Rastogi Ranjit Banwait Devina Singh Hale Toklu Lexie Finer Dipendra Parajuli Latha Ganti
author_sort	Vaibhav Rastogi
title	Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
title_short	Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
title_full	Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
title_fullStr	Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
title_full_unstemmed	Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
title_sort	prevalence of hepatopancreatic injury and clinical outcomes in patients with covid-19 in usa
publisher	BMC
publishDate	2021
url	https://doaj.org/article/84440671453442d6a475304089dd969f
work_keys_str_mv	AT vaibhavrastogi prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa AT ranjitbanwait prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa AT devinasingh prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa AT haletoklu prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa AT lexiefiner prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa AT dipendraparajuli prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa AT lathaganti prevalenceofhepatopancreaticinjuryandclinicaloutcomesinpatientswithcovid19inusa
_version_	1718442634316349440

Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA

Ejemplares similares